Despite the high level of public attention devoted to breast cancer awareness, more than 60 percent of respondents in a new national survey commissioned by Pfizer Inc. say they know little to nothing about metastatic breast cancer. 1
The survey is the first of its kind to examine the general public’s understanding of metastatic breast cancer, which affects up to 250,000 women and men in the U.S. today. 2 The survey results reveal widely held misperceptions about the causes, treatments and outcomes related to metastatic breast cancer, underscoring the need for better efforts to educate the public about the disease. 1 To help encourage these efforts and drive greater support for people living with metastatic breast cancer and their caregivers, Pfizer and the Avon Foundation for Women have partnered to establish the Avon-Pfizer Metastatic Breast Cancer Grants Program.
In total, the unprecedented partnership will award up to $1 million in grants to advocacy, academic and other not-for-profit organizations who serve the metastatic breast cancer community. The program will support initiatives to provide information and services that help people with metastatic breast cancer navigate the medical and emotional challenges associated with their disease.
“To date, the majority of public attention to breast cancer has centered on early disease, highlighting screening, early detection and survivorship, and leaving those living with metastatic breast cancer feeling isolated from the broader breast cancer movement,” said Andy Schmeltz, regional president, North America, Pfizer Oncology. “By partnering with the Avon Foundation for Women on the Metastatic Breast Cancer Grants Program, we hope to move the needle on metastatic breast cancer education across a variety of audiences – patients, their loved ones, the broader breast cancer community, and the general public.”“The Avon Foundation is pleased to partner with Pfizer on this new grants program to harness our collective energy, improving the lives of those with metastatic disease,” said Marc Hurlbert, executive director of the Avon Foundation for Women Breast Cancer Crusade. “This new Avon-Pfizer partnership will address the gaps identified in the Pfizer survey and launch recommendations and reports into action to further support for people living with the disease. Our hope is that one day, all patients with metastatic breast cancer can access the unique care and services they need.”